

1 **First Phase 1b, single-center, age de-escalation trial of the *P. falciparum***
2 **blood-stage malaria vaccine candidate RH5.1/Matrix-M™:**
3 **a delayed boost regimen induces high levels of functional antibodies**
4 **in 5-17 month old Tanzanian infants**

5
6 Sarah E. Silk^{1,2,3}, Wilmina F. Kalinga^{4,#}, Jo Salkeld^{1,2,3,#}, Ivanny M. Mtaka⁴, Saumu Ahmed⁴, Florence
7 Milando⁴, Ababacar Diouf⁵, Caroline K. Bundi^{6,7}, Neema Balige⁴, Omar Hassan⁴, Catherine G. Mkindi⁴,
8 Stella Rwezaula⁸, Thabit Athumani⁴, Sarah Mswata⁴, Nasoro S. Lilolime⁴, Beatus Simon⁴, Hania Msami⁴,
9 Mohamed Mohamed⁴, Damiano M. David⁴, Latipha Mohammed⁴, Gloria Nyaulingo⁴, Bakari Mwalimu⁴,
10 Omary Juma⁴, Tunu G. Mwamlima⁴, Ibrahim A. Sasamalo⁴, Rose P. Mkumbange⁴, Janeth J. Kamage⁴,
11 Jordan R. Barrett^{1,2,3}, Lloyd D. W. King^{1,2,3}, Mimi M. Hou^{1,2,3}, David Pulido², Cecilia Carnrot⁹, Alison M.
12 Lawrie^{2,10}, Rachel E. Cowan^{1,2,3}, Fay L. Nugent^{1,2}, Rachel Roberts^{1,2,3}, Jee-Sun Cho^{1,2,3}, Carole A. Long⁵,
13 Carolyn M. Nielsen^{1,2,3}, Kazutoyo Miura⁵, Simon J. Draper^{1,2,3,10,*}, Ally I. Olotu^{4,*}, and Angela M.
14 Minassian^{1,2,3,10,*†}.

15
16 ¹ Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.

17 ² Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus,
18 Oxford, OX3 7LE, UK.

19 ³ Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford,
20 OX1 3QU, UK.

21 ⁴ Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania.

22 ⁵ Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.

23 ⁶ Kenya Medical Research Institute (KEMRI) Centre for Geographic Medicine Coast, KEMRI-Wellcome Trust
24 Research Programme, Kilifi, Kenya.

25 ⁷ KEMRI-Wellcome Trust Research Programme – Accredited Research Centre, Open University, Kilifi, Kenya.

26 ⁸ Muhimbili National Hospital, Dar es Salaam, Tanzania.

27 ⁹ Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden.

28 ¹⁰ NIHR Oxford Biomedical Research Centre, Oxford, UK.

29 #,* These authors contributed equally.

30 † Corresponding author: Angela M. Minassian (angela.minassian@bioch.ox.ac.uk).

Silk SE *et al.*

31 This research was funded in part by the UK Medical Research Council (MRC) [Grant number:
32 MR/P020593/1 and MR/K025554/1]. For the purpose of Open Access, the author has applied a CC BY
33 public copyright licence to any Author Accepted Manuscript (AAM) version arising from this
34 submission.

35 **Abstract**

36 **Background**

37 RH5.1 is a soluble protein vaccine candidate for blood-stage *Plasmodium falciparum* malaria, previously
38 trialed in healthy UK adults in combination with AS01_B adjuvant. Here, RH5.1 was formulated with
39 Matrix-M™ adjuvant to assess safety and immunogenicity in a malaria-endemic adult and pediatric
40 population for the first time.

41 **Methods**

42 We conducted a Phase 1b, single-center, dose-escalation, age de-escalation, first-in-human trial of
43 RH5.1/Matrix-M™ in Bagamoyo, Tanzania. Healthy adults (18-45 years) and infants (5-17 months) were
44 recruited to receive the RH5.1/Matrix-M™ vaccine candidate in a variety of dosing regimens, including
45 monthly dosing (0-1-2 month) or delayed booster dosing (0-1-6 month) using a 10 µg dose of RH5.1, or
46 delayed fractional booster dosing (0-1-6 month) with the first two doses of RH5.1 at 50 µg and the third
47 dose at 10 µg. All RH5.1 protein doses were formulated with 50 µg Matrix-M™ adjuvant. Primary
48 outcomes for vaccine safety included solicited and unsolicited adverse events after each vaccination,
49 along with any serious adverse events (SAEs) during the study period. Secondary outcome measures for
50 immunogenicity included the concentration and avidity of anti-RH5.1 serum IgG antibodies by ELISA
51 and their percentage growth inhibition activity (GIA) *in vitro* against *P. falciparum* parasites using
52 purified IgG. All participants receiving at least one dose of vaccine were included in the primary analyses.

53 **Findings**

54 Between 25th January 2021 and 15th April 2021 a total of 60 adults and infants were enrolled; 57 of these
55 completed the vaccination series, and 55 completed 22 months of follow-up post-third vaccination.
56 Vaccinations were well-tolerated across both age groups. There were five SAEs involving four infant
57 participants during the trial, none of which were deemed related to vaccination. RH5-specific T cell and
58 serum antibody responses were induced by vaccination. The anti-RH5 serum IgG responses were
59 significantly higher in the 5-17 month old infant groups as compared to adults. Serum antibody responses

60 contracted over time post-third vaccination, but a similar hierarchy of responses across the age groups
61 was maintained after 22 months follow-up (674 days post-third vaccination). Vaccine-induced anti-RH5
62 antibodies showed *in vitro* GIA with comparable functional quality across all age groups and dosing
63 regimens. The highest anti-RH5 serum IgG responses were observed post-third vaccination in the 5-17
64 month old infants vaccinated with the 0-1-6 month delayed booster regimen using the 10 µg dose of
65 RH5.1 (median 723 µg/mL; range: 450-1436 µg/mL), resulting in 100 % (11/11 infants) showing >60 %
66 GIA following dilution of total IgG to 2.5 mg/mL (median 88 %; range: 73-97 %).

67 **Interpretation**

68 The RH5.1/Matrix-M™ vaccine candidate shows an acceptable safety and reactogenicity profile and
69 highly promising antibody immunogenicity in 5-17 month old infants residing in a malaria-endemic area.
70 The 0-1-6 month delayed booster regimen in 5-17 month old infants induced the highest levels of
71 functional GIA reported to-date following human vaccination, with all infants achieving a level of GIA
72 previously associated with protective outcome against blood-stage *P. falciparum* challenge in non-human
73 primates. These data support onward efficacy assessment of this vaccine candidate against clinical
74 malaria in young African infants.

75 **Funding**

76 The European and Developing Countries Clinical Trials Partnership (EDCTP).

77 **Trial Registration**

78 ClinicalTrials.gov: NCT04318002.

79 **Introduction**

80 Malaria is a leading global cause of disease and death despite decades of interventions. In 2022 there were
81 249 million cases and 608,000 deaths, with over 75% of deaths occurring in children under the age of five
82 in sub-Saharan Africa ¹. Despite a welcome reduction in the global burden of disease between 2000 and
83 2015, this progress has since stalled and even reversed ¹. Malaria prevention services were significantly
84 disrupted by the COVID-19 pandemic, and drug and insecticide resistance, along with conflict and
85 climate change, together pose significant ongoing threats; highly effective vaccines thus remain urgently
86 needed.

87 Encouragingly, two malaria vaccines targeting the sporozoite stage of *Plasmodium falciparum*,
88 RTS,S/AS01 (Mosquirix™) and R21/Matrix-M™, have now been recommended by the World Health
89 Organization (WHO); both vaccines have shown efficacy against clinical malaria in young African
90 infants in Phase 3 clinical trials ^{2,3}. However, higher efficacy vaccines with improved durability remain
91 needed, ideally without necessitating four doses. Moreover, efficacy against blood-stage infection with
92 pre-erythrocytic vaccines requires creation and maintenance of sterile immunity, a high hurdle. Thus,
93 addition of a complementary blood-stage vaccine strategy is attractive; such vaccines aim to prevent
94 invasion of erythrocytes by merozoites, leading to control and clearance of blood-stage parasitemia,
95 prevention of morbidity and reduced transmission ⁴. Additionally, a multi-stage malaria vaccine,
96 consisting of partially effective anti-sporozoite and anti-merozoite components, provides a potential route
97 to achieving a highly effective intervention; whereby the blood-stage component would eliminate any
98 parasites that escaped the first (pre-erythrocytic) line of defense.

99
100 *P. falciparum* reticulocyte-binding protein homologue 5 (RH5) is the most advanced blood-stage vaccine
101 candidate antigen. RH5 forms part of an invasion complex ^{5,6} and is both highly conserved and essential
102 for invasion, where it mediates parasite binding to basigin on the erythrocyte surface ⁷. *In vivo* protection

103 induced by RH5 vaccination was first demonstrated in an *Aotus* monkey model using a stringent
104 heterologous *P. falciparum* challenge ⁸. Importantly, this study demonstrated that *in vivo* protection
105 correlated with functional antibody activity, as measured by the *in vitro* growth inhibition activity (GIA)
106 assay, and it enabled protective threshold levels of GIA and anti-RH5 serum IgG antibody to be defined.
107 GIA was subsequently validated as a mechanistic immune correlate in *Aotus* by passive transfer of anti-
108 RH5 monoclonal antibody ⁹.

109
110 The first RH5-based vaccine candidate to enter clinical trials was a viral-vectored formulation, consisting
111 of the recombinant replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated
112 orthopoxvirus modified vaccinia virus Ankara (MVA). These were delivered to healthy UK adults in an 8
113 week prime-boost regimen (VAC057; ClinicalTrials.gov: NCT02181088). The viruses were safe and
114 well-tolerated and elicited a functional antibody response with cross-strain *in vitro* GIA ¹⁰, although the
115 level of GIA was below the *Aotus*-defined threshold of protection. However, given that another malaria
116 vaccine candidate based on the same ChAd63 prime-MVA boost platform ¹¹ had previously been shown
117 to elicit 10-fold higher antibody levels in African infants (the target population for *P. falciparum* malaria
118 vaccines) as compared with UK adults, testing of the ChAd63-MVA RH5 candidate in a malaria-endemic
119 setting was warranted. A Phase 1b age de-escalation, dose escalation trial was therefore subsequently
120 undertaken in Tanzania (VAC070; NCT03435874). This showed that the same viral-vectored RH5
121 vaccine candidate induced 10-fold higher anti-RH5 IgG responses in Tanzanian 6-11 month old infants as
122 compared with UK adults, thus achieving the highest levels of functional GIA reported following human
123 malaria vaccination at the time ¹². In an attempt to optimize antibody quantity further, a full-length RH5
124 soluble protein vaccine, called RH5.1, was subsequently developed ^{13,14} and initially trialled in UK adults
125 in a Phase 1/2a trial with GlaxoSmithKline's (GSK's) AS01_B adjuvant (VAC063; NCT02927145). This
126 induced 10-fold higher antibody levels as compared to the viral-vectored RH5 in UK adults ¹⁵. Anti-RH5
127 serum IgG responses in UK adults were also more durable when the third dose was delivered at 6 months

128 and at one-fifth of the initial dose (a so-called “delayed fractionation” (DFx) regimen), as compared to
129 responses seen after three full (identical) doses given one month apart ¹⁵.

130
131 Here we report a Phase 1b clinical trial in Tanzanian adults and infants [VAC080; NCT04318002] that
132 was therefore designed to assess the safety and immunogenicity of the RH5.1 soluble protein vaccine
133 candidate, now formulated with Matrix-M™ adjuvant from Novavax. Following first-in-human safety
134 assessment of this new formulation in adults, three different dosing regimens were assessed in the target
135 infant population, 5-17 months of age (to align with delivery of R21/Matrix-M™ and RTS,S/AS01). This
136 trial was designed to assess whether the levels of anti-RH5 serum IgG and functional GIA associated with
137 a protective outcome in the *Aotus* monkey – *P. falciparum* challenge model could also be achieved in
138 vaccinated African infants, and thereby inform decision-making on the progression of this RH5-based
139 vaccine candidate to Phase 2b field efficacy testing.

140 **Results**

141 **Study recruitment and vaccinations**

142 The VAC080 Phase 1b trial was conducted in the Bagamoyo district of Tanzania. Malaria incidence in
143 the district was estimated to range from 539 cases per 1000-person years in higher transmission areas to
144 76 cases per 1000-person years in lower transmission areas in 2020 ¹⁶. The protocol recruitment plan was
145 to recruit two groups of healthy adults (aged 18-45 years) and three groups of 5-17 month old infants
146 from Bagamoyo town, an area of relatively low malaria transmission within the district. The study was
147 also designed to include a fourth infant group with relatively higher malaria pre-exposure, to assess for
148 potential impact of prior malaria exposure on the immunogenicity of the RH5.1 /Matrix-M™ vaccine
149 candidate. 185 participants were screened and 60 of these (N=12 adults and N=48 infants) were enrolled
150 into the VAC080 Phase 1b trial (**Figure 1**). Prior to study start, an anti-parasite serological assay was
151 established to provide a relative assessment of previous malaria exposure in the 5-17 month old infant age
152 group. Serum IgG responses to parasite lysate of infants living in both urban (Dunda and Magomeni,
153 N=90) and rural (Yombo and Fukayosi, N=15) wards within Bagamoyo district were used to define
154 relative “low” versus “high” malaria pre-exposure thresholds relevant to this study population (**Figure**
155 **S1A**). Within the infant cohort, 156 were tested for anti-parasite lysate responses during screening
156 (**Figure S1B**), with N=36 recruited from those defined as relatively “low” prior malaria exposure and
157 N=12 recruited from those defined as relatively “high” prior malaria exposure (**Figure S1C**).

158
159 Vaccinations began on 25th January 2021 and all 22 month post-third vaccination follow-up visits were
160 completed by 27th July 2023. Group allocation was open label and non-randomized and enrolment
161 proceeded in a dose escalation and age de-escalation fashion. Independent safety reviews were conducted
162 by the Data Safety and Monitoring Board (DSMB) between every age de-escalation and dose-escalation
163 step in the protocol. All vaccinations were administered via the intramuscular route in the deltoid and, in
164 every case, the indicated dose of RH5.1 protein was formulated prior to injection with 50 µg Matrix-M™

165 adjuvant. Recruitment began with six adults in group “Adults 10M” who received 10 µg RH5.1 at 0, 1
166 and 2 months (monthly regimen), followed by six adults in group “Adults DFx” who received 50 µg
167 RH5.1 at 0 and 1 months and 10 µg RH5.1 at 6 months (delayed-fractional regimen; DFx). Following a
168 safety review, the four groups of twelve 5-17 month old infants were enrolled. Those in group “Infants
169 10M” (monthly regimen) and group “Infants 10D” (10 µg RH5.1 at 0, 1 and 6 months; delayed regimen)
170 were recruited in parallel first, followed by group “Infants DFx”, who received the DFx regimen. Finally
171 the group “High Infants DFx” was recruited as the relatively higher malaria pre-exposure cohort, and they
172 also received the DFx regimen. Two participants in the “High Infants DFx” cohort were recruited with
173 anti-parasite lysate IgG slightly below the serological threshold (**Figure S1C**); following a review they
174 continued to receive the remaining vaccinations and study visits as scheduled.

175
176 The median age of adult participants was 23.5 years (range 20-30 years) and the median age of infant
177 participants was 12 months (range 5-17 months), with comparable ranges across the groups (**Figure S2**).
178 Similar numbers of males and females were enrolled across the infant age groups, however, although
179 there were no sex-based exclusion criteria, no adult female participants were screened or recruited. There
180 were three withdrawals during the vaccination period. Two participants withdrew after the first study
181 vaccination, one in “Adults 10M” and one in “High Infants DFx”, and one participant in “Infants 10D”
182 withdrew after the second vaccination. One withdrawal was due to the participant moving out of the study
183 area and none were related to adverse experiences with study procedures. All other participants received
184 the study vaccinations as scheduled. Two infant participants died during the post-vaccination follow-up
185 period for reasons unrelated to the study or the study vaccinations as detailed below. All other participants
186 completed follow-up out to 22 months post-final vaccination.

187

188 **Outcomes and estimation**

189 **Reactogenicity and safety**

190 There were no safety concerns during the course of the trial. The majority of local solicited adverse events
191 (AEs) in both adults and infants were graded as mild to moderate in severity (**Figure 2**). Severe local
192 solicited AEs were reported in one adult and three infant participants. The most common local solicited
193 AE across all groups was swelling, reported after 18 % of vaccine doses (32/175 doses); this mainly
194 occurred after the second and third doses and was mild (11 %; 19/175 doses), moderate (7 %; 12/175) or
195 severe (1 %; 1/175) in graded severity. A slightly higher proportion of participants receiving the higher 50
196 µg dose of RH5.1 (those in groups “Adults DFx”, “Infants DFx” and “High Infants DFx”) experienced
197 local solicited AEs of moderate to severe grade (14 %; 12/88 doses) compared to the lower dose groups
198 (10 %; 9/87). Severe swelling and induration occurred in one adult participant from the lower dose group
199 (“Adults 10M”) after the final vaccine administration; this resolved spontaneously within 7 days. All
200 other local AEs in adults resolved by 72 hours post-vaccine administration. In the two infant DFx regimen
201 groups, three infants developed severe and one developed moderate induration after receiving their final
202 delayed dose. The majority of local solicited AEs in infants resolved within 72 hours post-vaccination,
203 and all resolved by day 8.

204
205 The majority of systemic solicited AEs were mild in severity, and there were no severe systemic solicited
206 AEs reported (**Figure 2**). The most frequent systemic solicited AEs were mild subjective fever and mild
207 objective fever, reported after 18 % (31/175) and 7 % (12/175) of vaccinations, respectively, occurring
208 only in infants. One case of moderate severity subjective fever and one case of moderate severity
209 objective fever were reported in the higher dose infant groups after receiving the second study
210 vaccination. Vomiting, diarrhea, reduced oral intake and reduced activities were also experienced by
211 infants only and were all of mild severity. All systemic AEs reported by adult participants were mild in
212 severity, except for one participant who reported moderate grade headache on day one following both the

213 first and second study vaccinations. In adults, most systemic solicited AEs resolved within 48 hours after
214 vaccination and in infants most systemic solicited AEs resolved within 72 hours of vaccine
215 administration. All systemic solicited AEs resolved by day 8.

216
217 Unsolicited AEs deemed at least possibly related to study interventions were all of mild or moderate
218 severity (**Figure S3**). There was only one unsolicited AE in the adult groups – one participant reported an
219 episode of mild dizziness six days following the third study vaccination which resolved spontaneously on
220 the same day. There were five different unsolicited AEs in infants; all resolved within 8 days with the
221 exception of one participant who was diagnosed with a helminth infection which was deemed probably
222 related to vaccination due to the temporal association with study vaccination and lasted for 53 days. All
223 unsolicited AEs had resolved by the end of the study period.

224
225 There were five serious adverse events (SAEs) involving four infant participants during the trial, none of
226 which were deemed related to vaccination (**Figure S4**). Two of the five SAEs had a fatal outcome: one
227 infant with stage IV neuroblastoma and one infant with acute respiratory failure secondary to herbal
228 intoxication. The independent trial DSMB was informed of both cases and determined there was no
229 relationship to study vaccinations. There were no AEs of special interest (AESIs) or suspected unexpected
230 serious adverse reactions (SUSARs) during the course of the trial.

231
232 The most frequent laboratory abnormality identified in the 28-day post-vaccination period in adults was
233 lymphopenia, occurring in 17 % (1/6) of “Adults 10M” participants and 33 % (2/6) of “Adults DFx”
234 participants (**Figure S5**). All laboratory AEs occurring during this period in adults were mild in graded
235 severity and resolved by the end of the study period, apart from one participant who had mild
236 lymphopenia when they withdrew following their day 14 visit (post-first vaccination). The most frequent
237 laboratory abnormality identified in the 28-day post-vaccination period in infants was anemia, occurring

238 in 58 % of participants (7/12) in the “Infants 10M”, “Infants 10D” and “Infants DFx” groups, and in 42 %
239 (5/12) in the “High Infants DFx” group. The maximum severity of anemia was moderate grade and in all
240 cases had resolved by the final study visit (maximum duration 154 days). The majority of other laboratory
241 AEs occurring during this period in infants were mild to moderate and all had resolved by the final study
242 visit.

243
244 There were three severe grade laboratory AEs in infants in the 28 days following vaccination (**Figure S5**).
245 One participant in the “High Infants DFx” group developed severe neutropenia at 7 days post-second
246 vaccination which was temporally associated with a diagnosis of eczema with superimposed bacterial
247 infection. This had improved to mild by day 14 and resolved completely by the third vaccination. One
248 participant in the “Infants 10D” group developed severe neutropenia at 7 days post-second vaccination
249 which resolved by day 14 and was temporally associated with a diagnosis of pneumonia. One participant
250 in the “High Infants DFx” group developed severe eosinophilia at 7 days post-third vaccination which
251 persisted at moderate grade until 28 days post-vaccination and had resolved by 84 days. There were no
252 symptoms suggestive of allergy and stool microscopy did not show any evidence of helminth infection.
253 This infant was well throughout this time period with no concerns apart from an isolated episode of fever
254 on day 22.

255
256 All participants tested negative for malaria by microscopy at screening and were subsequently tested by
257 microscopy at the second and third vaccination visits and monthly thereafter. Two participants in the
258 “High Infants DFx” group (with higher prior malaria exposure) tested positive during study visits in the
259 follow-up period (at 4 and 12 months post-third vaccination); these participants were clinically well and
260 received anti-malarial treatment in the community. In addition, one participant in the “Infants DFx” group
261 tested positive for malaria outside of the study during chemotherapy for neuroblastoma (see above section
262 on SAEs).

263

264 **Immunogenicity**

265 The magnitude of the serum anti-RH5 IgG antibody response was measured over time by ELISA against
266 full-length RH5 (RH5.1) recombinant protein. Almost all participants showed background level responses
267 at baseline (data not shown); consistent with numerous other immuno-epidemiological data that suggest
268 RH5 is not a dominant target of naturally-acquired malaria immunity^{10,17,18}. Fourteen days following two
269 vaccinations (denoted “V2+14”) of either 10 µg or 50 µg RH5.1 formulated with Matrix-M™ adjuvant,
270 responses were comparable across the two doses within the adult or infant cohorts (**Figure 3A,B**).
271 However, the magnitude of the antibody response showed a clear age-dependence, with significantly
272 higher responses observed in the 5-17 month old infants (**Figure S6A**); here the adult cohorts showed
273 median responses ranging from 38-52 µg/mL anti-RH5.1 IgG compared to the infant cohorts with ~4-5
274 fold-higher median responses ranging from 200-230 µg/mL.

275

276 Responses then declined over time and were significantly lower prior to the third vaccination (V3) in all
277 participants receiving the delayed or delayed-fractional boost at month 6, as compared to those receiving
278 a final boost at month 2 (**Figure 3A,B**). Subsequently, 14 days following the third dose (V3+14; day 70
279 for monthly cohorts and day 196 for delayed and delayed-fractional cohorts), significantly higher
280 responses (~2-3-fold) were maintained in the 5-17 month old infants, as compared to adults, regardless of
281 vaccination with either the monthly or Dfx regimen (**Figure S6B**). Here, within the adult groups,
282 responses were moderately but significantly higher at V3+14 in those receiving the Dfx as compared to
283 10M regimen, with median responses of 138 µg/mL and 81 µg/mL, respectively (**Figure 3A**). In contrast,
284 responses at V3+14 in the 5-17 month old infants receiving these same two regimens were comparable,
285 with median responses at ~290 µg/mL (**Figure 3B**). There was also no difference in the serum anti-RH5
286 IgG response at any time-point between the two infant cohorts who received the same Dfx regimen, but
287 who differed in baseline malaria pre-exposure status (**Figure 3C**). However, in contrast, the infants

288 receiving the 10D regimen showed significantly higher responses, reaching a median of 723 $\mu\text{g/mL}$, with
289 all infants in this group showing anti-RH5 serum IgG responses at the V3+14 time-point above the level
290 associated with protection against *P. falciparum* blood-stage challenge in *Aotus* monkeys ⁸ (**Figure 3B**).

291
292 To further explore immune responses following the third vaccination, we also assessed the avidity of the
293 anti-RH5 serum IgG response and the induction of RH5-specific IFN- γ T cell responses. Here, delayed
294 and DFx boosting, as opposed to monthly boosting, were both associated with significantly more avid
295 anti-RH5 IgG responses in adults and infants (**Figure S7**). In contrast, the anti-RH5 IFN- γ T cell
296 response, as assessed by *ex-vivo* ELISpot assay ¹⁵, was comparable across all groups, regardless of age or
297 vaccination regimen (**Figure S8**).

298
299 Anti-RH5 serum IgG antibody responses subsequently declined over time (**Figure S6C**), but a similar
300 pattern of immunogenicity to the peak response was maintained at ~1 year post-third vaccination
301 (V3+309), although no significant differences were observed at ~2 years (V3+674) between the monthly
302 and DFx regimens within the adult and infant cohorts (**Figure 3A,B**). The highest responses were
303 maintained at V3+674 in the Infants 10D cohort, with a median of 65 $\mu\text{g/mL}$; these were significantly
304 higher than those in the Infants 10M cohort with median of 16 $\mu\text{g/mL}$ (**Figure 3B**).

305
306 Serum samples were next analyzed for *in vitro* functional anti-parasitic activity at the GIA Reference
307 Center (NIAID/NIH). Purified total IgG was normalized to a starting concentration of 10 mg/mL and
308 tested against *P. falciparum* (3D7 clone) parasites using the standardized single-cycle GIA assay.
309 Samples at baseline (pre-vaccination) were negligible (<20 % GIA), with a single exception of one adult
310 who had 58 % GIA (**Figure 4A**), however large increases in overall GIA were observed post-
311 RH5.1/Matrix-M™ vaccination (**Figure 4B**). Here, at the V3+14 time-point (14 days post-dose 3) and
312 using 10 mg/mL total IgG, median levels ranged from 83-87 % and 95-98 % GIA across the adult and

313 infant groups, respectively. All total IgG samples with >40 % GIA at 10 mg/mL were subsequently
314 titrated using a 2-fold dilution series in the assay (**Figure S9A**). The overall levels of GIA mirrored the
315 previous serology, with infants overall showing higher levels of GIA as compared to adults and as
316 measured using 2.5 mg/mL total purified IgG. Moreover, the infants vaccinated with the 10D regimen
317 showed the highest levels of GIA, significantly outperforming the 10M and DFX regimens tested in the
318 other infant groups (**Figure 4C**). There were also no differences seen in the levels of GIA between the
319 two infant cohorts who differed in baseline malaria pre-exposure status and received the same DFX
320 regimen (**Figure 4D**).

321
322 The GIA showed a strong relationship to the concentration of RH5.1-specific IgG present in the total IgG
323 used in the assay and as measured by ELISA (**Figure 4E**). The concentration of RH5.1-specific
324 polyclonal IgG required to give 50 % GIA (EC_{50}) was highly comparable across all the groups (regardless
325 of age, vaccine regimen and malaria pre-exposure status at baseline). Analysis across all groups combined
326 showed a GIA EC_{50} = 14.3 μ g/mL (95% CI: 13.4-15.2 μ g/mL). This functional “quality” readout of the
327 RH5.1/Matrix-M™ vaccine candidate, i.e. the concentration of antigen-specific IgG required to achieve
328 50 % GIA, was consistent with our previously reported data following vaccination of healthy volunteers
329 in the UK or Tanzania with viral-vectored RH5 or RH5.1/AS01_B^{10,12,15} (**Figure S9B**).

330
331 We previously reported an association between the *in vitro* GIA assay and *in vivo* protection outcome
332 following RH5 vaccination and *P. falciparum* blood-stage challenge in *Aotus* monkeys, with protected
333 animals showing >60 % GIA at 2.5 mg/mL purified IgG^{8,9}. A similar association was observed in a
334 controlled human malaria infection (CHMI) trial in healthy UK adults vaccinated with RH5.1/AS01_B,
335 although this threshold level of GIA was not reached in that study¹⁵. Notably, in the VAC080 trial, all
336 four groups of vaccinated infants showed median levels of GIA at 2.5 mg/mL total IgG over the level of
337 60 % GIA (**Figure S10A**). The Infants 10D group showed the highest median level of GIA at 88 % with

Silk SE *et al.*

338 all participants (11/11) above the 60 % GIA target threshold at day 14 following the third vaccination
339 (**Figure 4C**). This level of GIA is the highest level of functional GIA achieved following human
340 vaccination to date (**Figure S10B**).

341 **Discussion**

342 Here we report a dose-escalation, age de-escalation, first-in-human clinical trial of the RH5.1/Matrix-M™
343 vaccine candidate, assessed in a malaria-endemic population. These data in healthy Tanzanian adults and
344 5-17 month old infants show that this adjuvanted protein subunit vaccine formulation has a favorable
345 safety and reactogenicity profile, highly comparable to data from Phase 1b malaria vaccine trials using the
346 R21 immunogen formulated with the same Matrix-M™ adjuvant^{19,20}. Independent review concluded
347 none of the five SAEs (involving four infant participants) that occurred during the trial, including two
348 with fatal outcomes, were related to vaccination (see **Supplementary Information**). These occurred
349 against a similar backdrop child mortality rate (aged 1-5 years) of 26.5/1000 and infant mortality rate
350 (aged 0-1 years) of 53.0/1000 in Bagamoyo District as last recorded in 2012²¹. Including this trial, safety
351 data have now been reported for 193 healthy volunteers (109 adults, 18 children and 66 infants)
352 vaccinated with RH5-based vaccines^{10,12,15}, all showing similar safety and tolerability profiles, whilst
353 Matrix-M™ adjuvant is now a component in vaccines for malaria and Covid-19 that are licensed for
354 human use^{3,22}. On-going Phase 1/2 trials, including a Phase 2b efficacy trial in >200 infants 5-17 months
355 of age (VAC091; NCT05790889), continue to monitor the safety of RH5.1/Matrix-M™ vaccination.

356
357 The RH5.1/Matrix-M™ vaccine candidate was immunogenic for anti-RH5 IFN- γ T cell responses and
358 serum IgG antibody across all age groups and dosing regimens. The levels of peripheral T cell response
359 observed by ELISPOT assay were not dissimilar to those previously reported in UK adults immunized
360 with the RH5.1/AS01_B formulation using the same dosing regimens¹⁵. While the contribution of IFN- γ -
361 secreting T cells to RH5-mediated malaria immunity in humans remains unclear, it is likely that RH5-
362 specific CD4⁺ T cells are needed to help B cell responses. Indeed, previous work in UK adults has shown
363 RH5.1/AS01_B can induce RH5-specific circulating T follicular helper (Tfh) cell responses and that these
364 correlate with both RH5-specific memory B cells and serum antibody²³. Work remains on-going to

365 investigate B and Tfh cell response phenotypes in the Tanzanian infant population vaccinated here with
366 RH5.1/Matrix-M™.

367

368 Priming of Tanzanian adults with two doses of 10 or 50 µg RH5.1 formulated with 50 µg Matrix-M™
369 led to similar anti-RH5 serum IgG responses two weeks after the second dose. Notably, however,
370 following the third dose, the 0-1-6 month DFX regimen induced significantly more avid and higher levels
371 of anti-RH5 serum IgG, as compared to the 0-1-2 monthly regimen; consistent with our previous
372 observations in UK adults vaccinated with the same dosing regimens of RH5.1 with AS01_B adjuvant¹⁵.
373 These serum IgG responses were better maintained over time in the DFX regimen vaccinees for at least
374 ~1 year following the third dose, although responses declined by ~2 years. In line with this, we have also
375 reported enhanced circulating RH5-specific memory B cell responses in adults vaccinated with the DFX
376 (as opposed to monthly) dosing regimen, along with a higher frequency of RH5-specific (and putatively
377 long-lived) plasma cells in the bone marrow that correlated strongly with the serum anti-RH5 IgG
378 response^{24,25}.

379

380 Interestingly, these observations in adult vaccinees were only partly replicated in the 5-17 month old
381 infants. Responses were again similar two weeks after the second vaccination, regardless of RH5.1
382 protein priming dose, however, following the third vaccination the monthly and DFX regimens performed
383 comparably, whereas significantly higher anti-RH5 serum IgG responses were induced in those infants
384 receiving a delayed, but not fractionated dose, of RH5.1 protein at 6 months. The underlying reasons for
385 this improvement with the delayed, as opposed to DFX, regimen remain to be determined, although
386 circulating levels of vaccine-specific antibody may affect vaccine responsiveness²⁶ and this cohort
387 primed twice with 10 µg RH5.1 with Matrix-M™ showed lower anti-RH5 serum IgG responses at the
388 time of third vaccination (month 6) as compared to those in the DFX regimen group who were primed
389 twice with a higher 50 µg RH5.1 dose. In line with our observations here, trials of RTS,S/AS01 showed

390 improved outcome measures with a DFX regimen, as opposed to 0-1-2 monthly dosing, in healthy US
391 adults ²⁷, however no improvement in field efficacy when tested in 5-17 month old infants ²⁸. Notably,
392 these DFX regimens tested with RTS,S/AS01 fractionated the dose of adjuvant and antigen, unlike our
393 trials where a fractionated dose of antigen is delivered in a full dose of adjuvant. Nevertheless, our data
394 suggest a delayed boosting, as opposed to DFX, regimen may be more optimal in this younger age group
395 and this warrants further investigation.

396
397 Regardless of vaccination regimen, peak anti-RH5 serum IgG responses in the 5-17 month old infants
398 were significantly higher than those induced in adults – a phenomenon now consistently observed with
399 numerous other malaria subunit vaccine candidates including viral-vectored and recombinant antigen-in-
400 adjuvant formulations such as R21/Matrix-MTM ^{11,12,19,29,30}. These data bode well for future assessment of
401 multi-stage malaria vaccine strategies, whereby a blood-stage RH5 component could be trialed in
402 combination with the licensed pre-erythrocytic vaccines. The very high levels of anti-RH5 serum IgG
403 induced in the 5-17 month old infants translated into the highest levels of functional GIA observed in
404 human vaccinees to-date. Indeed, overall GIA largely mirrored the serological responses, and all infants
405 vaccinated with the 0-1-6 month delayed boost regimen (who averaged ~700 µg/mL RH5-specific IgG at
406 the peak of the response) exceeded the threshold level of *in vitro* GIA that our work has previously
407 associated with a protective outcome in *Aotus* monkeys challenged with blood-stage *P. falciparum* ^{8,9}.
408 Importantly, this GIA threshold was also reached in 75% of infants vaccinated with the 0-1-2 month
409 regimen, suggesting RH5 vaccination could be aligned with the current delivery schedule for the primary
410 series of RTS,S/AS01 and/or R21/Matrix-MTM. The functional quality of serum antibody induced by
411 RH5.1/Matrix-MTM (i.e. GIA per µg anti-RH5 IgG) was also highly similar across all age groups and
412 vaccination regimens tested here, and also highly similar to that reported in all previous clinical trials of
413 vaccine candidates based on the full-length RH5 molecule ^{10,12,15}. Consistent with previous observations
414 using RH5.1/AS01_B in UK adults ^{15,25}, all the delayed booster regimens tested here in adults and infants

415 also showed improvement in the avidity of anti-RH5 serum IgG, however, this did not impact the
416 functional quality of these IgG in the assay of GIA. These observations have now been explained by
417 analysis of anti-RH5 human mAbs that showed delayed boosting leads to improvement in the anti-RH5
418 antibody dissociation rates, but not in the antibody association rates which are strongly correlated with
419 GIA potency³¹.

420
421 Previous work on historical blood-stage vaccine candidates targeting the AMA1 antigen suggested that
422 naturally-occurring anti-malarial antibody responses could interfere with vaccine-induced IgG³², whilst
423 other studies have suggested such antibodies may interact additively or synergistically with anti-RH5 IgG
424 in terms of GIA³³. We therefore also assessed the DFx regimen in 5-17 month old infants who had
425 experienced relatively higher levels of malaria exposure prior to study recruitment. Our data indicated no
426 apparent impact of these anti-malarial responses on RH5.1/Matrix-MTM immunogenicity or functional
427 GIA. Whether much higher levels of existing anti-malarial natural immunity at the time of RH5 vaccine
428 priming may enhance or interfere with vaccine outcomes now remains to be determined in larger field
429 trials at sites of higher malaria endemicity.

430
431 The main limitations of this trial were the relatively small numbers of participants recruited from an area
432 of low to moderate malaria transmission, and that in the adult groups only males volunteered to
433 participate. Nonetheless, the very high levels of GIA achieved in this trial indicate that a 0-1-6 month
434 delayed boost regimen with RH5.1/Matrix-MTM may protect the 5-17 month old target population against
435 blood-stage *P. falciparum* malaria. In light of this, the RH5.1/Matrix-MTM vaccine candidate has since
436 progressed to a Phase 2b field efficacy trial in Burkina Faso (VAC091; NCT05790889) to assess efficacy
437 against clinical malaria following monthly or delayed boost vaccination.

438 **Methods**

439 **Study Design**

440 The VAC080 trial was an open-label, age de-escalation, dose-escalation study, conducted according to the
441 principles of the current revision of the Declaration of Helsinki 2013 and in full conformity with the ICH
442 guidelines for Good Clinical Practice (GCP). It was approved by the Oxford Tropical Research Ethics
443 Committee in the UK (reference 9-20), and the following authorities in Tanzania: the Ifakara Health
444 Institute Institutional Review Board (reference 49-2020), the National Institute for Medical Research, the
445 National Health Research Ethics Sub-Committee and the Tanzania Medicines and Medical Devices
446 Authority (reference TMDA0020/CTR/0006/01). The VAC080 trial was registered on ClinicalTrials.gov
447 (NCT04318002). The study was conducted at Ifakara Health Institute Clinical Trial Facility, Bagamoyo
448 Research and Training Centre, Tanzania.

449
450 We report here the safety, reactogenicity and immunogenicity profile of vaccination with the RH5.1
451 protein¹⁴ given with 50 µg Matrix-M™ adjuvant (Novavax) in monthly, delayed and delayed-fractional
452 regimens up until 674 days (22 months) post-final study vaccination. The Consolidated Standards of
453 Reporting Trials (CONSORT) guidelines were followed.

454
455 **Participants**

456 Healthy adults (18-45 years) and infants (5-17 months) residing in Bagamoyo District, Tanzania, with a
457 negative malaria blood film at screening, were eligible for inclusion in the study. Enrolment was into six
458 groups (two adult and four infant groups) according to age, timing of enrolment and malaria pre-exposure
459 status (infants only). A full list of inclusion and exclusion criteria are listed in the study protocol which is
460 included within the Supplementary Appendix.

461

462 Each participant (or guardian) signed or thumb-printed an informed consent form at the in-person
463 screening visit and consent was verified before each vaccination. The independent DSMB periodically
464 reviewed the study progress and safety data according to a safety review schedule, including prior to each
465 age de-escalation or dose escalation step.

466

467 **Procedures**

468 **Safety Analysis**

469 Following each vaccination, each participant was visited at home on days 1 (infants only), 3, 4, 5 and 6 by
470 a community health worker for assessment and any solicited and unsolicited AEs were recorded. At days
471 1 (adults only), 2, 7, 14 and 28 post-vaccination, participants were seen at the clinical research facility. In
472 addition, participants attended the facility for follow-up on days 84, 112, 309 and 674 post-third
473 vaccination. Solicited AEs were collected at visits up to 7 days post-vaccination and unsolicited AEs were
474 collected at visits up to 28 days post-vaccination. SAEs were collected at all visits. Observations (heart
475 rate, temperature and blood pressure measurements) were taken at the clinic visits from the day of
476 vaccination until day 84 post-third vaccination. Blood tests for exploratory immunology were taken at all
477 visits except those occurring 2 days after each vaccination and 7 days after the first vaccination. Blood
478 samples for safety (full blood count, alanine aminotransferase and creatinine) were carried out at
479 screening and at all clinic visits except those occurring on days 1-2 post-vaccination and on 28 days post-
480 second vaccination for the delayed regimen groups.

481

482 Solicited AEs were defined as being at least possibly related to vaccination. The likely causality and
483 grading of unsolicited AEs and SAEs were assessed as described in the protocol. Unsolicited AEs were
484 classified according to MedDRA (version 26.0).

485

486 **Outcomes**

487 Primary outcome measures for vaccine safety included solicited and unsolicited AEs after each
488 vaccination, along with any SAEs during the study period. The primary outcome analysis was conducted
489 on the safety analysis population which included participants who received at least the first dose of
490 vaccine in the study. Solicited AEs were collected for seven days after each study vaccination and the
491 maximum severity reported for each solicited systemic and local AE by each participant after each
492 vaccination was summarized by group. Unsolicited AEs were collected for 28 days after each study
493 vaccination and those deemed at least possibly related to study vaccination are reported. SAEs were
494 collected for the entire study period and all SAEs, regardless of causality, are reported.

495
496 The secondary outcome measures for immunogenicity were the concentration and avidity of anti-RH5.1
497 serum IgG antibodies by ELISA and their percentage GIA *in vitro* using purified IgG, as well as cellular
498 immunogenicity to RH5.1 as measured by ELISPOT and/or (reported elsewhere) flow cytometry.

499
500 Exploratory outcome measures included the assessment of the frequency of RH5-specific plasma cells
501 from bone marrow aspirates at baseline and 4 weeks post-third vaccinations, reported elsewhere ²⁴.

502

503 **Vaccines**

504 The design, production and preclinical testing of RH5.1 has been reported previously in detail ^{13,14}.

505 Briefly, RH5.1 is a soluble protein immunogen based on the full-length *P. falciparum* reticulocyte-

506 binding protein homologue 5 (RH5). The protein is produced by secretion from *Drosophila melanogaster*

507 Schneider-2 cells. RH5.1 was developed at the University of Oxford and an initial batch produced to

508 Good Manufacturing Practice (GMP) by the Clinical Biomanufacturing Facility in Oxford.

509

510 Matrix-M™ adjuvant was manufactured by Novavax AB (Uppsala, Sweden). It is a potent, saponin-based
511 adjuvant and comprises of partially-purified extracts of the bark of the *Quillaja saponaria* Molina tree,
512 phosphatidylcholine and cholesterol. Matrix-M™ has demonstrated a favorable safety profile, as well as
513 enhancement of cellular and humoral immune responses to a range of vaccine candidates and is licensed
514 for human use in other malaria and Covid-19 vaccines ^{3,22}.

515

516 **Peripheral Blood Mononuclear Cell (PBMC), Plasma and Serum Preparation**

517 Blood samples were collected into lithium heparin-treated vacutainer blood collection systems (Becton
518 Dickinson, UK). PBMC were isolated and used within 6 h in fresh assays as previously described ³⁴.
519 Excess cells were frozen in fetal calf serum (FCS) containing 10 % dimethyl sulfoxide and stored in
520 liquid nitrogen. Plasma samples were stored at -80 °C. For serum preparation, using untreated
521 vacutainers, blood samples were stored at room temperature and then the clotted blood was centrifuged
522 for 5 min (1000 *xg*). Serum was stored at -80 °C.

523

524 **Anti-parasite Lysate ELISA**

525 Serum antibody levels to parasite lysate were assessed by standardized ELISA methodology previously
526 described ^{12,16,35}. Schizont extract from *P. falciparum* (3D7 clone) parasites produced by the GIA
527 Reference Laboratory, NIAID, NIH, was adsorbed overnight at 4 °C to 96 well NUNC-Immuno Maxisorp
528 plates (Thermo Fisher Scientific) at an equivalent of 5x10² parasites per µL. Test sera were diluted in 1 %
529 milk in Dulbecco's phosphate buffered saline (DPBS) and added in triplicate to plates following blocking
530 with 5 % milk in DPBS (Sigma). A reference standard and internal control samples from a pool of N=34
531 "high" malaria pre-exposed serum samples, from the Bagamoyo Clinical Trial Facility-Ifakara Health
532 Institute (BCTF-IHI) Biobank, plus blank wells, were included. Use of these samples received ethical
533 approval from the Ifakara Health Institute Institutional Review Board (IHI/IRB/No: 49-2020). Bound
534 antibodies were detected using goat anti-human IgG conjugated to alkaline phosphatase (Sigma),

535 developed using 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma) and absorbance at 405 nm
536 (OD₄₀₅) was determined on a BioTek Elx808 reader with Gen5 software. Antibody units were assigned
537 using the reciprocal dilution of the standard giving an optical density of 1.0 at OD₄₀₅. The standard curve
538 and Gen5 software v3.04 (Agilent) were then used to convert the OD₄₀₅ of test samples to arbitrary units
539 (AU). “Low” and “high” malaria pre-exposure thresholds were first defined at <25th percentile (20 AU)
540 and >75% percentile (85 AU) of all N=105 population test samples. However, due to a large number of
541 screening failures making recruitment difficult these were redefined as <75% percentile (71 AU) from
542 “urban” wards, Magomeni and Dunda, and >60% percentile (140 AU) from “rural” wards, Fukayosi and
543 Yombo, within Bagamoyo district. These criteria maintained a clear difference in anti-malarial antibody
544 levels between the two cohorts.

545

546 **RH5 ELISA**

547 Anti-RH5 total IgG ELISAs were performed against full-length RH5 protein (RH5.1) using standardized
548 methodology as previously described^{10,12,15}. The reciprocal of the test sample dilution giving an OD₄₀₅ of
549 1.0 in the standardized assay was used to assign an ELISA unit value of the standard. A standard curve
550 and Gen5 ELISA software v3.04 (BioTek, UK) were used to convert the OD₄₀₅ of individual test samples
551 into AU. These responses in AU are reported in µg/mL following generation of a conversion factor by
552 calibration-free concentration analysis as reported previously¹⁰.

553

554 **Avidity ELISA**

555 Anti-RH5.1 IgG antibody avidity was assessed by sodium thiocyanate (NaSCN)-displacement ELISA
556 using previously described methodology^{10,15}. The concentration of NaSCN required to reduce the
557 OD₄₀₅ to 50% of that without NaSCN was used as a measure of avidity (IC₅₀).

558

559 **Assay of Growth Inhibition Activity (GIA)**

560 Standardized assays were performed by the GIA Reference Center, NIH, USA, using previously
561 described methodology³⁶. Each sample was tested in three independent replication assays using three
562 different batches of red blood cells (RBC), and the median of these three results was used to generate the
563 final dataset as per previously reported RH5 vaccine trials and methodology^{12,15,37}. For each assay, in
564 brief, protein G purified IgG samples were incubated with RBC infected with synchronized *P. falciparum*
565 3D7 clone parasites in a final volume of 40 μ L for 40 h at 37 °C, and the final parasitemia in each well
566 was quantified by biochemical determination of parasite lactate dehydrogenase. All purified IgG samples
567 were tested initially at 10 mg/mL final test well concentration. For samples with >40 % GIA at 10
568 mg/mL, a dilution series was tested and used to determine the concentration that gave 50 % GIA (EC₅₀).
569

570 **IFN- γ ELISPOT**

571 Fresh PBMC were used in all assays using a previously described protocol^{10,12,15}. Spots were counted
572 using an ELISPOT counter (Autoimmun Diagnostika (AID), Germany). Results are expressed as IFN- γ
573 spot-forming units (SFU) per million PBMC with unstimulated control well responses subtracted from
574 peptide-stimulated well measurements.

575

576 **Statistical Analysis**

577 Data were analyzed using GraphPad Prism version 10.1 for Windows (GraphPad Software Inc.,
578 California, USA). All tests used were two-tailed and are described in the text. A value of $P < 0.05$ was
579 considered significant.

580 **Author Contributions**

581 Conceived and performed the experiments: SES, WFK, JS, IMM, FM, AD, CKB, NB, OH, CGM, SR, SM,
582 NSL, BS, HM, MM, DMD, LM, GN, BM, OJ, TGM, IAS, RPM, JJK, JRB, LDWK, MMH, DP, CAL,
583 CMN, KM, SJD, AIO, AMM.

584 Analyzed the data: SES, WFK, JS, TA, KM, SJD, AIO, AMM.

585 Project Management: SA, CC, AML, REC, FLN, RR, J-SC.

586 Wrote the paper: SES, JS, SJD, AMM.

587 **Acknowledgments**

588 The authors are grateful to Julie Furze, Jing Jin, Daniela Tomescu, Rebecca Ashfield, Kate Skinner,
589 Susanne Hodgson, Cheryl Turner, Jack Quaddy, Subarna Sriskantharajah and Hilary Vitkus for assistance
590 and Sally Pelling-Deeves for arranging contracts (University of Oxford); Richard Tarrant, Helena
591 Parracho, Robert Smith and Catherine Green (Clinical Biomanufacturing Facility, University of Oxford);
592 Jenny Reimer (Novavax); the independent DSMB for their insightful safety oversight (Brian Angus,
593 Karim Manji, Roma Chilengi, Kwaku Poke Asante, William Macharia and Greg Fegan); and all the study
594 participants.

595
596 This work was funded in part by the European and Developing Countries Clinical Trials Partnership
597 (EDCTP) Multi-Stage Malaria Vaccine Consortium (MMVC) [RIA2016V-1649-MMVC]; an African
598 Research Leader Award to AIO from the UK Medical Research Council (MRC) [MR/P020593/1], this
599 award was jointly funded by the UK MRC and the UK Department for International Development (DFID)
600 under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the
601 European Union; the UK MRC [MR/K025554/1]; the National Institute for Health and Care Research
602 (NIHR) Oxford Biomedical Research Centre (BRC), the views expressed are those of the authors and not
603 necessarily those of the NHS, the NIHR, or the Department of Health; the GIA work was supported by

Silk SE *et al.*

604 the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID) and
605 by an Interagency Agreement (AID-GH-T-15-00001) between the United States Agency for International
606 Development (USAID) Malaria Vaccine Development Program (MVDP) and NIAID. The findings and
607 conclusions are those of the authors and do not necessarily represent the official position of USAID.
608 CMN held a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellowship [209200/Z/17/Z]. SJD is a
609 Jenner Investigator.

610

611 **Conflict of Interest Statement**

612 LDWK and SJD are named inventors on patent applications relating to RH5 malaria vaccines. AMM has
613 an immediate family member who is an inventor on patent applications relating to RH5 malaria vaccines.
614 All other authors have declared that no conflict of interest exists.

615

616 **Data and Materials Availability**

617 Requests for materials should be addressed to the corresponding authors.

618 **References**

- 619 1. World Health O. World malaria report 2023. Geneva: World Health Organization; 2023.
- 620 2. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in
621 infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet*
622 2015; **386**(9988): 31-45.
- 623 3. Dattoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-
624 M in African children: a multicentre, double-blind, randomised, phase 3 trial. *Lancet* 2024; **403**(10426):
625 533-44.
- 626 4. Draper SJ, Sack BK, King CR, et al. Malaria Vaccines: Recent Advances and New Horizons. *Cell*
627 *Host Microbe* 2018; **24**(1): 43-56.
- 628 5. Scally SW, Triglia T, Evelyn C, et al. PCRCR complex is essential for invasion of human
629 erythrocytes by Plasmodium falciparum. *Nature microbiology* 2022; **7**(12): 2039-53.
- 630 6. Ragotte RJ, Higgins MK, Draper SJ. The RH5-CyRPA-Ripr Complex as a Malaria Vaccine
631 Target. *Trends Parasitol* 2020; **36**(6): 545-59.
- 632 7. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte
633 invasion by Plasmodium falciparum. *Nature* 2011; **480**(7378): 534-7.
- 634 8. Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-Based Vaccine Is Efficacious against
635 Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. *Cell Host*
636 *Microbe* 2015; **17**(1): 130-9.
- 637 9. Douglas AD, Baldeviano GC, Jin J, et al. A defined mechanistic correlate of protection against
638 Plasmodium falciparum malaria in non-human primates. *Nat Commun* 2019; **10**(1): 1953.
- 639 10. Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing
640 antimalarial antibodies that inhibit RH5 invasion complex interactions. *JCI Insight* 2017; **2**(21): 96381.
- 641 11. Bliss CM, Drammeh A, Bowyer G, et al. Viral Vector Malaria Vaccines Induce High-Level T
642 Cell and Antibody Responses in West African Children and Infants. *Mol Ther* 2017; **25**(2): 547-59.
- 643 12. Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody immunogenicity of a viral-vectored
644 RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. *Med* 2023; **4**(10): 668-86.
- 645 13. Hjerrild KA, Jin J, Wright KE, et al. Production of full-length soluble Plasmodium falciparum
646 RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system. *Sci Rep* 2016;
647 **6**: 30357.
- 648 14. Jin J, Tarrant RD, Bolam EJ, et al. Production, quality control, stability, and potency of cGMP-
649 produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. *NPJ Vaccines*
650 2018; **3**: 32.
- 651 15. Minassian AM, Silk SE, Barrett JR, et al. Reduced blood-stage malaria growth and immune
652 correlates in humans following RH5 vaccination. *Med* 2021; **2**(6): 701-19.
- 653 16. Mwamlima TG, Mwakasungula SM, Mkindi CG, et al. Understanding the role of serological and
654 clinical data on assessing the dynamic of malaria transmission: a case study of Bagamoyo district,
655 Tanzania. *Pan Afr Med J* 2022; **43**: 60.
- 656 17. Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is
657 susceptible to vaccine-inducible cross-strain neutralizing antibody. *Nat Commun* 2011; **2**: 601.
- 658 18. Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage
659 malaria vaccine. *Sci Transl Med* 2014; **6**(247): 247ra102.
- 660 19. Sang S, Dattoo M, Otieno E, et al. Safety and immunogenicity of varied doses of R21/Matrix-M?
661 vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children,
662 and infants in Kilifi-Kenya [version 1; peer review: awaiting peer review]. *Wellcome open research* 2023;
663 **8**(450).

- 664 20. Venkatraman N, Tiono AB, Bowyer G, et al. Phase I assessments of first-in-human
665 administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and
666 Burkinabe volunteers. *medRxiv* 2019: 19009282.
- 667 21. https://www.nbs.go.tz/nbs/takwimu/census2012/Mortality_and_Health_Monograph.pdf.
- 668 22. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19
669 Vaccine. *N Engl J Med* 2021; **385**(13): 1172-83.
- 670 23. Nielsen CM, Ogbe A, Pedroza-Pacheco I, et al. Protein/AS01B vaccination elicits stronger, more
671 Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors.
672 *Cell Rep Med* 2021; **2**(3): 100207.
- 673 24. Barrett JR, Silk SE, Mkindi CG, et al. Analyses of human vaccine-specific circulating and bone
674 marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage
675 malaria antigens. *Front Immunol* 2023; **14**: 1193079.
- 676 25. Nielsen CM, Barrett JR, Davis C, et al. Delayed boosting improves human antigen-specific Ig and
677 B cell responses to the RH5.1/AS01B malaria vaccine. *JCI Insight* 2023; **8**(2).
- 678 26. McNamara HA, Idris AH, Sutton HJ, et al. Antibody Feedback Limits the Expansion of B Cell
679 Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. *Cell Host*
680 *Microbe* 2020; **28**(4): 572-85 e7.
- 681 27. Regules JA, Cicatelli SB, Bennett JW, et al. Fractional Third and Fourth Dose of RTS,S/AS01
682 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and
683 Immunogenicity Study. *J Infect Dis* 2016; **214**(5): 762-71.
- 684 28. Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01(E) malaria vaccine
685 administered according to different full, fractional, and delayed third or early fourth dose regimens in
686 children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
687 *Lancet Infect Dis* 2022; **22**(9): 1329-42.
- 688 29. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after
689 vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. *PLoS*
690 *Med* 2014; **11**(7): e1001685.
- 691 30. Leroux-Roels G, Leroux-Roels I, Clement F, et al. Evaluation of the immune response to
692 RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive
693 adults. *Hum Vaccin Immunother* 2014; **10**(8): 2211-9.
- 694 31. Barrett JR, Pipini D, Wright ND, et al. Analysis of the Diverse Antigenic Landscape of the
695 Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype.
696 *bioRxiv* 2023: 2023.10.04.560576.
- 697 32. Miura K, Perera S, Brockley S, et al. Non-apical membrane antigen 1 (AMA1) IgGs from Malian
698 children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. *PLoS One*
699 2011; **6**(6): e20947.
- 700 33. Willcox AC, Huber AS, Diouf A, et al. Antibodies from malaria-exposed Malians generally
701 interact additively or synergistically with human vaccine-induced RH5 antibodies. *Cell Rep Med* 2021;
702 **2**(7): 100326.
- 703 34. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia Clinical Evaluation of the Safety and
704 Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA
705 Vaccine Vectors. *PLoS One* 2012; **7**(2): e31208.
- 706 35. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. Development and
707 characterization of a standardized ELISA including a reference serum on each plate to detect antibodies
708 induced by experimental malaria vaccines. *Vaccine* 2008; **26**(2): 193-200.
- 709 36. Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1:
710 an asexual blood-stage vaccine for Plasmodium falciparum malaria. *Infect Immun* 2005; **73**(6): 3677-85.
- 711 37. Miura K, Diouf A, Fay MP, et al. Assessment of precision in growth inhibition assay (GIA) using
712 human anti-PfRH5 antibodies. *Malar J* 2023; **22**(1): 159.

713 **Figure Legends**

714 **Figure 1: Trial profile.**

715 “Adults 10M” (adults aged 18-45 years) received 10 µg RH5.1 with 50 µg Matrix-M™ at 0, 1 and 2
716 months. “Adults Delayed-Fractional [DFx]” (adults aged 18-45 years) received 50 µg RH5.1 with 50 µg
717 Matrix-M™ at 0 and 1 months and 10 µg RH5.1 with 50 µg Matrix-M™ at 6 months. “Infants 10M”
718 (infants aged 5-17 months) received 10 µg RH5.1 with 50 µg Matrix-M™ at 0, 1 and 2 months. “Infants
719 10D” (infants aged 5-17 months) received 10 µg RH5.1 with 50 µg Matrix-M™ at 0, 1 and 6
720 months. “Infants DFx” (infants aged 5-17 months) received 50 µg RH5.1 with 50 µg Matrix-M™ at 0 and
721 1 months and 10 µg RH5.1 with 50 µg Matrix-M™ at 6 months. “High Infants DFx” (infants aged 5-17
722 months with higher prior malaria exposure based on anti-parasite lysate IgG at screening) received 50 µg
723 RH5.1 with 50 µg Matrix-M™ at 0 and 1 months and 10 µg RH5.1 with 50 µg Matrix-M™ at 6 months.
724 The main reason for participant withdrawal was consent withdrawal which was not due to adverse
725 experience. Two participants died during the course of the study unrelated to study vaccination. All
726 participants who received at least a single dose of RH5.1/Matrix-M™ were analyzed as part of the safety
727 cohort. All participants who received at least a single dose of RH5.1/Matrix-M™ for whom data
728 concerning immunogenicity endpoint measures were available were analyzed as part of the
729 immunogenicity cohort. Two participants in the “High Infants DFx” group were recruited in error at
730 below the “high” exposure threshold and are included in the immunogenicity analysis as indicated in
731 subsequent figures.

732

733 **Figure 2: Solicited adverse events (AEs) following vaccination.**

734 Participants (or their carers) were asked about the presence of systemic and local AEs on the day of each
735 study vaccination and for the following 7 days. The maximum severity reported by each participant for

736 each AE after each study vaccination is shown. 10M = monthly vaccination regimen; DFx = delayed-
737 fractional regimen; 10D = delayed regimen.

738

739 **Figure 3. Serum antibody response to vaccination.**

740 Median and individual anti-RH5.1 serum total IgG responses as measured by ELISA are shown at 14
741 days post-second vaccination (V2+14), day of third vaccination (V3), and 14, 309 and 674 days post-third
742 vaccination (V3+14 / 309 / 674) for (A) “Adults 10M” (N=5) and “Adults DFx” (N=6), and (B) “Infants
743 10M” (N=10-12), “Infants 10D” (N=11-12) and “Infants DFx” (N=8-12). “Infants 10M” and “Infants
744 10D” data were pooled at V2+14 due to identical immunization and dosing regimen at this time-point.
745 The red dotted line indicates the protective threshold associated with protection against *P. falciparum*
746 blood-stage challenge in RH5-vaccinated *Aotus* monkeys (~300 µg/mL)⁸. (C) ELISA data shown for the
747 “Infants DFx” (N=8-12) and “High Infants DFx” (N=10-11) groups. Open symbols indicate N=2
748 participants who did not meet high pre-exposure threshold. Group kinetic responses are shown in **Figure**
749 **S6C**. Analyses used Mann-Whitney test between dosing regimens within age groups only, **P* < 0.05, ***P*
750 < 0.01; and Kruskal-Wallis with Dunn’s multiple comparison test for V3, V3+14, V3+309 and V3+674 in
751 (B) **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001.

752

753 **Figure 4. Functional GIA induced by RH5 vaccination.**

754 *In vitro* GIA of total IgG purified from serum was assessed against 3D7 clone *P. falciparum* parasites.
755 Median and individual values are shown for each group at (A) Baseline (day 0) at 10 mg/mL total IgG;
756 (B) 14 days post-third vaccination (V3+14) at 10 mg/mL total IgG; and (C) V3+14 at 2.5 mg/mL total
757 IgG (“Adults 10M” N=4-6; “Adults DFx” N=6; “Infants 10M” N=12; “Infants 10D” N=11; “Infants
758 DFx” N=12). Open circle datapoint in (C) is arbitrarily set at 0 % GIA and for the sample not titrated in
759 the assay. Red dashed line in (C) indicates threshold of 60 % GIA associated with protective outcome in

760 RH5-vaccinated and *P. falciparum* challenged *Aotus* monkeys⁸. Analysis between infant dosing regimens
761 by Kruskal-Wallis with Dunn's multiple comparison test, * $P < 0.05$, ** $P < 0.01$. (D) GIA of samples at
762 baseline and V3+14 tested at 10 mg/mL and 2.5 mg/mL total IgG from the "Infants DFX" (N=12) and
763 "High Infants DFX" (N=10-12) cohorts. Open symbols indicate N=2 participants who did not meet the
764 high pre-exposure threshold. Analysis used Mann-Whitney test to compare between the two groups; ns =
765 not significant. (E) V3+14 samples were titrated in the GIA assay using a 2-fold dilution series starting at
766 10 mg/mL. Relationship between GIA data from the dilution series and the concentration of anti-RH5.1-
767 specific IgG used in the assay as measured by ELISA in the total IgG is shown. Non-linear regression
768 curves (constrained to $>0\%$ and $<100\%$ GIA) are shown for each group. The EC_{50} (concentration of anti-
769 RH5.1 polyclonal IgG that gives 50% GIA) was calculated (dashed line represents 50% GIA) using data
770 points pooled across all groups ($r^2 = 0.95$, N=487).

Figure 1





Figure 2



Percentage of volunteers

Nil
 Mild
 Moderate
 Severe

Figure 3

